American Thoracic Society International Conference

American Thoracic Society International Conference

May 27, 2015
4 min watch

VIDEO: Expert discusses the biologics of asthma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Geoffrey L. Chupp, MD, director of the Yale Center for Asthma and Airways Disease, discusses the biologics of asthma.

Chupp says that with drugs in development targeting the Interluekin-5 pathway as well as Interluekin-13, patients with non-allergic asthma will have other options for treatment.

“The addition of additional agents is good for patients with the disease and good in general because it is increasing awareness about the importance of achieving control in your patients and what lack of control means and it is providing other opportunities for patients that don't fall into the allergic category,” Chupp told